Methacrylic Acid

Methacrylic Acid

SCHEMBL22554414

C=C(C)C(=O)O.C=C(C)C(=O)O.OCCCCCCCCCCCCCCCCCCCO

nearest known ligand 0.48

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR84 Q9NQS5 1/20 0.48
FFAR1 O14842 1/20 0.48
FFAR4 Q5NUL3 1/20 0.48
FNTA P49354 2/20 0.41
FNTB P49356 2/20 0.41
TSHR P16473 3/20 0.41
LMNA P02545 2/20 0.41
ALDH1A1 P00352 2/20 0.41
HSD17B10 Q99714 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.39
KDM4E B2RXH2 1/20 0.39
CAMK2A Q9UQM7 1/20 0.39
TDP1 Q9NUW8 2/20 0.36
TGFBR1 P36897 1/20 0.35
CYP4F2 P78329 1/20 0.33
CYP4A11 Q02928 1/20 0.33
THRB P10828 1/20 0.32
PGGT1B P53609 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
1,6-Hexanediol SCHEMBL18140102 1.00 GPR84 (0.48) GPR84FFAR1FFAR4FNTAFNTB
1,6-Hexanediol SCHEMBL18139252 1.00 GPR84 (0.48) GPR84FFAR1FFAR4FNTAFNTB
1,6-Hexanediol SCHEMBL22023211 1.00 GPR84 (0.48) GPR84FFAR1FFAR4FNTAFNTB
Methacrylic Acid SCHEMBL22554430 1.00 GPR84 (0.48) GPR84FFAR1FFAR4FNTAFNTB
Methacrylic Acid SCHEMBL22554407 1.00 GPR84 (0.48) GPR84FFAR1FFAR4FNTAFNTB
Methacrylic Acid SCHEMBL22554424 1.00 GPR84 (0.48) GPR84FFAR1FFAR4FNTAFNTB
Methacrylic Acid SCHEMBL22554428 1.00 GPR84 (0.48) GPR84FFAR1FFAR4FNTAFNTB
Methacrylic Acid SCHEMBL22554401 1.00 GPR84 (0.48) GPR84FFAR1FFAR4FNTAFNTB
Methacrylic Acid SCHEMBL22554405 1.00 GPR84 (0.48) GPR84FFAR1FFAR4FNTAFNTB
Methacrylic Acid SCHEMBL72635 1.00 GPR84 (0.48) GPR84FFAR1FFAR4FNTAFNTB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3728339-B1 COMPOSITION FOR OPHTHALMOLOGICAL PRODUCTS AMO Ireland (IE) 2022-07-06 EP claimed
US-11359031-B2 Composition for ophthalmological products Johnson & Johnson Surgical Vision, Inc. (US) 2022-06-14 US claimed
EP-3728339-A1 COMPOSITION FOR OPHTHALMOLOGICAL PRODUCTS Merck Patent GmbH (DE) 2020-10-28 EP claimed
US-20200332041-A1 COMPOSITION FOR OPHTHALMOLOGICAL PRODUCTS MERCK PATENT GMBH (DE) 2020-10-22 US claimed
CN-111712523-A Ophthalmic product composition 默克专利股份有限公司 2020-09-25 CN claimed
EP-4182737-B1 OPTICALLY ACTIVE DEVICES AMO Ireland (IE) 2024-07-03 EP disclosed
US-20240142665-A1 OPTICALLY ACTIVE DEVICES MERCK PATENT GMBH (DE) 2024-05-02 US disclosed
US-20240117092-A1 OPTICALLY ACTIVE DEVICES AMO Ireland (IE) 2024-04-11 US disclosed
EP-4284787-A1 OPTICALLY ACTIVE DEVICES AMO Ireland (IE) 2023-12-06 EP disclosed
EP-4263513-A1 OPTICALLY ACTIVE DEVICES AMO Ireland (IE) 2023-10-25 EP disclosed
US-20230273455-A1 OPTICALLY ACTIVE DEVICES JOHNSON & JOHNSON SURGICAL VISION INC (US) 2023-08-31 US disclosed
US-20230273456-A1 OPTICALLY ACTIVE DEVICES JOHNSON & JOHNSON SURGICAL VISION INC (US) 2023-08-31 US disclosed
EP-3728339-B1 COMPOSITION FOR OPHTHALMOLOGICAL PRODUCTS AMO Ireland (IE) 2022-07-06 EP disclosed
WO-2022128832-A1 OPTICALLY ACTIVE DEVICES MERCK PATENT GMBH (DE) 2022-06-23 WO disclosed
EP-4015512-A1 OPTICALLY ACTIVE DEVICES AMO Ireland (IE) 2022-06-22 EP disclosed
US-11359031-B2 Composition for ophthalmological products Johnson & Johnson Surgical Vision, Inc. (US) 2022-06-14 US disclosed
WO-2022012798-A1 OPTICALLY ACTIVE DEVICES MERCK PATENT GMBH (DE) 2022-01-20 WO disclosed
WO-2022012799-A1 OPTICALLY ACTIVE DEVICES MERCK PATENT GMBH (DE) 2022-01-20 WO disclosed
US-20200332041-A1 COMPOSITION FOR OPHTHALMOLOGICAL PRODUCTS MERCK PATENT GMBH (DE) 2020-10-22 US disclosed
CN-111712523-A Ophthalmic product composition 默克专利股份有限公司 2020-09-25 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230273456-A1 OPTICALLY ACTIVE DEVICES PDE6C, PDE6D, PDE6A GPR84 958/4885FFAR1 3756/4885FFAR4 3898/4885
US-20230273455-A1 OPTICALLY ACTIVE DEVICES PDE6C, PDE6A, PDE6D GPR84 828/4885FFAR1 3958/4885FFAR4 4101/4885
US-20240117092-A1 OPTICALLY ACTIVE DEVICES PDE6C, UACA, PDE6A GPR84 527/4885FFAR1 3928/4885FFAR4 4124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.